A POC Study of TAC-201

A phase IIa proof-of-concept study of TAC-201 in cedar pollinosis

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221355

Enrollment

Registered

2011-01-18

Start date

2011-01-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cedar pollen allergy

Interventions

investigational material(s) Generic name etc : TAC-201 INN of investigational material : Therapeutic category code : 449 Other antiallergic agents Dosage and Administration for Investigational materi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Distinct symptoms of cedar pollinosis during the cedar pollen allergy season in 2010, with the severity of moderate or higher.

Exclusion criteria

Exclusion criteria: Previous participation in the study of TAC-201.

Design outcomes

Primary

Measure	Time frame
Efficacy Proportion of symptom-free days(%) calculated by clinical symptom score.	—

Secondary

Measure	Time frame
Safety Adverse events	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026